Which is better, LBRX or LMAT?

On the Buffett-Fit framework, LeMaitre Vascular, Inc. (LMAT) currently grades higher than LBRX — 77/100 (B grade) vs 42/100 (D). That said, "better" depends on which framework you trust — LBRX wins on none; LMAT wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy LBRX or LMAT?

This page is an educational comparison, not investment advice. Both LBRX and LMAT are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is LBRX better than LMAT for value investing?

On the Buffett-style value-investing framework, LMAT currently grades higher — 77/100 vs 42/100, a 35-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between LBRX and LMAT on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). LBRX currently scores 42/100 (D grade); LMAT scores 77/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, LBRX or LMAT?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. LBRX and LMAT are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, LBRX or LMAT?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are LBRX and LMAT both Healthcare stocks?

Yes — both LB Pharmaceuticals Inc Common Stock (LBRX) and LeMaitre Vascular, Inc. (LMAT) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this LBRX vs LMAT comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

LB Pharmaceuticals

LeMaitre Vascular

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

LBRX

LB Pharmaceuticals

Market cap

$806.39M

Sector

Healthcare

LMAT

LeMaitre Vascular

Market cap

$2.23B

Sector

Healthcare

Overall winner

LeMaitre Vascular LMAT

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	LBRX	LMAT	Winner
Warren Buffett	42D	77B	LMAT
Benjamin Graham	50D	89A	LMAT
Philip Fisher	53C	81C	LMAT
Peter Lynch	12F	67B	LMAT
Joel Greenblatt	2F	56D	LMAT
Charlie Munger	55D	68D	LMAT
Terry Smith	64C	69D	LMAT

Side-by-side metrics

Metric	LBRX	LMAT
Market cap	$806.39M	$2.23B
P/E (TTM)	-	37.1x
EV/EBIT	-	36.6x
ROIC (TTM)	-9.93%	9.43%
Gross margin	0.0%	72.39%
Net margin	0.0%	24.35%
Revenue CAGR 5y	-	12.75%
EPS CAGR 5y	-	19.04%
Debt / Equity	0.0x	0.5x
Dividend yield	0.0%	0.84%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

LBRX leads on

P/E (TTM)-vs 37.1x+184%
EV/EBIT-vs 36.6x+158%
Debt / Equity0.0xvs 0.5x+97%

LMAT leads on

ROIC (TTM)9.43%vs -9.93%+195%
Gross margin72.39%vs 0.0%+100%
Net margin24.35%vs 0.0%+100%
Dividend yield0.84%vs 0.0%+100%

More like LBRX

LBRX vs IDXX LBRX vs 7741.T LBRX vs GMAB LBRX vs SUNPHARMA.NS LBRX vs HALO LBRX vs MTD

More like LMAT

LMAT vs IDXX LMAT vs 7741.T LMAT vs GMAB LMAT vs SUNPHARMA.NS LMAT vs HALO LMAT vs MTD

Read the full Buffett-Brain analysis for LBRX Read the full Buffett-Brain analysis for LMAT

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

LB Pharmaceuticals

LeMaitre Vascular

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

LBRX

LB Pharmaceuticals

Market cap

$806.39M

Sector

Healthcare

LMAT

LeMaitre Vascular

Market cap

$2.23B

Sector

Healthcare

Overall winner

LeMaitre Vascular LMAT

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	LBRX	LMAT	Winner
Warren Buffett	42D	77B	LMAT
Benjamin Graham	50D	89A	LMAT
Philip Fisher	53C	81C	LMAT
Peter Lynch	12F	67B	LMAT
Joel Greenblatt	2F	56D	LMAT
Charlie Munger	55D	68D	LMAT
Terry Smith	64C	69D	LMAT

Side-by-side metrics

Metric	LBRX	LMAT
Market cap	$806.39M	$2.23B
P/E (TTM)	-	37.1x
EV/EBIT	-	36.6x
ROIC (TTM)	-9.93%	9.43%
Gross margin	0.0%	72.39%
Net margin	0.0%	24.35%
Revenue CAGR 5y	-	12.75%
EPS CAGR 5y	-	19.04%
Debt / Equity	0.0x	0.5x
Dividend yield	0.0%	0.84%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

LBRX leads on

P/E (TTM)-vs 37.1x+184%
EV/EBIT-vs 36.6x+158%
Debt / Equity0.0xvs 0.5x+97%

LMAT leads on

ROIC (TTM)9.43%vs -9.93%+195%
Gross margin72.39%vs 0.0%+100%
Net margin24.35%vs 0.0%+100%
Dividend yield0.84%vs 0.0%+100%

More like LBRX

LBRX vs IDXX LBRX vs 7741.T LBRX vs GMAB LBRX vs SUNPHARMA.NS LBRX vs HALO LBRX vs MTD

More like LMAT

LMAT vs IDXX LMAT vs 7741.T LMAT vs GMAB LMAT vs SUNPHARMA.NS LMAT vs HALO LMAT vs MTD

Read the full Buffett-Brain analysis for LBRX Read the full Buffett-Brain analysis for LMAT

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.